Biosergen AB Logo

Biosergen AB

Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.

BIOSGN | ST

Overview

Corporate Details

ISIN(s):
SE0016013460 (+2 more)
LEI:
549300YD2OGUE7BMP925
Country:
Sweden
Address:
Fogdevreten 2, 171 65 Solna
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biosergen AB is a clinical-stage biotechnology company dedicated to developing innovative treatments for life-threatening invasive fungal infections. The company's lead candidate, BSG005, is a genetically improved, fungicidal polyene macrolide designed to offer a superior safety and potency profile compared to current antifungal therapies. BSG005 targets a wide spectrum of fungal pathogens and is primarily being developed for immunocompromised patients, such as those undergoing cancer treatment or organ transplantation. Originating from research at the Norwegian University of Science and Technology, the drug has received FDA Orphan Drug Designation. Through clinical trials and strategic collaborations, Biosergen aims to address the significant unmet medical need in treating severe and resistant fungal diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Biosergen AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Biosergen AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GC CELL CORPORATION Logo
Biotech firm offering cell/gene therapy CDMO services and developing immune cell cancer therapies.
South Korea 144510
GemVax & KAEL Co.,Ltd. Logo
Makes contamination controls for semiconductors & develops Alzheimer's therapeutics.
South Korea 082270
Gencurix Inc. Logo
Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.
South Korea 229000
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea 109820
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea 011000
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye GENIL
Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark GMAB
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea 225220

Talk to a Data Expert

Have a question? We'll get back to you promptly.